Biological Bank for Atrial Fibrillation and Stroke

Last updated: October 22, 2024
Sponsor: Hospices Civils de Lyon
Overall Status: Active - Recruiting

Phase

N/A

Condition

Stroke

Chest Pain

Atrial Fibrillation

Treatment

Blood taken

Blood taken

Clinical Study ID

NCT03611816
69HCL17_0538
2017-A03327-46
  • Ages > 18
  • All Genders

Study Summary

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years.

According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted.

The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.

Eligibility Criteria

Inclusion

Group 1a

  • Inclusion Criteria :

  • AF history

  • Exclusion Criteria :

  • No AF history

  • patient who didn't signed consent

Group 1b

  • Inclusion Criteria :

  • AF history

  • Scheduled electrophysiological exploration or AF ablation

  • Exclusion Criteria :

  • No AF history

  • pregnant women

  • patient who didn't signed consent

Group 1c

  • Inclusion Criteria :

  • AF/AT history

  • Stroke history

  • Exclusion Criteria :

  • No Stroke history

  • patient who didn't signed consent

Group 2

  • Inclusion Criteria :

  • patient over 80

  • ECG: sinusal rhythm

  • TTE : no left atrial dilatation

  • Exclusion Criteria :

  • atrial fibrillation history

  • TTE : Left atria >25cm², > 34m/m2), FEVG < 50%

  • ECG : QRS > 90 ms

  • cardiac pathologies (excepted hypertension and valvulopathies)

  • History of stroke and transient ischemic attack

  • patient who didn't signed consent

Group 3

  • Inclusion Criteria :

  • cryptogenic stroke or transient ischemic attack history before 50 yo

  • No AF history

  • Exclusion Criteria :

  • AF history

  • stroke or transient ischemic attack over 50 yo

  • patient who didn't signed consent

Study Design

Total Participants: 1000
Treatment Group(s): 2
Primary Treatment: Blood taken
Phase:
Study Start date:
April 23, 2018
Estimated Completion Date:
April 23, 2029

Connect with a study center

  • Service neurologie Centre hospitalier Fleyriat

    Bourg-en-Bresse, 01000
    France

    Active - Recruiting

  • Service d'urgences Neurovasculaires - service de neurologie vasculaire , Hôpital Pierre Wertheimer

    Bron, 69677
    France

    Active - Recruiting

  • Service de rythmologie, hôpital cardiologique Louis Pradel

    Bron, 69677
    France

    Active - Recruiting

  • Service de médecine gériatrique Centre hospitalier Lyon Sud, Groupement hospitalier Sud

    Pierre-Bénite, 69495
    France

    Active - Recruiting

  • Hôpital des charpennes

    Villeurbanne, 69100
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.